Project Grant R01DA066682
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $661K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- The National Institute on Drug Abuse awarded Drexel University $832,132 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate novel circuit mechanisms underlying opioid-induced dopamine elevations in the nucleus accumbens, operating beyond the canonical midbrain dopamine neuron pathway. The research explores how oxycodone enhances dopamine signals through local circuits in the nucleus accumbens, specifically examining the role of GABA and cholinergic...
- The National Institute on Drug Abuse awarded the University of Maryland, Baltimore $656,916 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate insular-amygdala conflict processing mechanisms in opioid use disorder relapse prevention. The project, titled "Insular-Amygdala Conflict Processing After Voluntary Abstinence," examines how the anterior insular cortex (AIC) processes conflicting motivations in individuals with opioid use disorder...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $198,164 on September 25, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research examining delta opioid receptor regulation of parvalbumin interneuron transmission and oxycodone-related behavior. The project investigates how delta opioid receptor signaling in parvalbumin-expressing GABAergic interneurons within the prefrontal cortex contributes to opioid use disorder symptoms,...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $466,363 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize allosteric crosstalk among opioid and endogenous neuromodulator receptors. The project uses cryo-electron microscopy to determine high-resolution structures of the mu-opioid receptor in active and inactive states bound to cannabinoids and neuropeptides including oxytocin. The work advances time-resolved cryo-EM...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $100,228 on October 8, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on opioid reward mechanisms. The award funds a project investigating the functional role of a novel cortical circuit connecting the dorsal peduncular nucleus to the ventral tegmental area in mediating opioid reward. The research employs barcoded anatomy resolved by sequencing combined with spatial...
- The National Institute on Drug Abuse awarded Louisiana State University $409,587 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate cell-type-specific excitability and molecular mechanisms underlying opioid seeking. The research examines how opioid use induces neural adaptations in the nucleus accumbens that increase drug-seeking behavior. The project focuses on intrinsic excitability changes in nucleus accumbens medium spiny neurons (MSNs)...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $1.788 million on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Type 1 hybrid effectiveness-implementation randomized controlled trial testing a remote intervention to prevent overdose among people who use stimulants and opioids. The award funds the R61 phase of a two-phase study designed to isolate the independent impact of remote education on overdose outcomes...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $409,750 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a secondary data analysis of national Medicaid claims examining variations in clinician responses to Prescription Drug Monitoring Program mandates. The recipient will analyze how emergency department, urgent care, and primary care clinicians adopt opioid prescribing regulations and policies differently,...
- The National Institute on Drug Abuse awarded The Medical College of Wisconsin, Inc. $468,000 on September 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to identify and interrogate glial gene signatures in volitional opioid seeking. The project addresses molecular adaptations underlying opioid addiction by characterizing transcriptional and epigenetic changes in glial populations—astrocytes, microglia, and oligodendrocytes—within mesolimbic reward regions. Prior...